- Home
- Publications
- Publication Search
- Publication Details
Title
How I treat smoldering multiple myeloma
Authors
Keywords
-
Journal
BLOOD
Volume 124, Issue 23, Pages 3380-3388
Publisher
American Society of Hematology
Online
2014-10-09
DOI
10.1182/blood-2014-08-551549
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
- (2014) Jens G. Lohr et al. CANCER CELL
- Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease
- (2014) Adriana Zingone et al. CYTOKINE
- Circulating miRNA markers show promise as new prognosticators for multiple myeloma
- (2014) A Rocci et al. LEUKEMIA
- Bildgebung bei „smoldering“ (asymptomatischem) multiplem Myelom
- (2014) M. Bhutani et al. RADIOLOGE
- miR-542-3p suppresses osteoblast cell proliferation and differentiation, targets BMP-7 signaling and inhibits bone formation
- (2014) J Kureel et al. Cell Death & Disease
- Smoldering multiple myeloma requiring treatment: time for a new definition?
- (2013) A. Dispenzieri et al. BLOOD
- Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma
- (2013) M. F. Kaiser et al. BLOOD
- miR-124 Inhibits STAT3 Signaling to Enhance T Cell–Mediated Immune Clearance of Glioma
- (2013) Jun Wei et al. CANCER RESEARCH
- BM mesenchymal stromal cell–derived exosomes facilitate multiple myeloma progression
- (2013) Aldo M. Roccaro et al. JOURNAL OF CLINICAL INVESTIGATION
- Progression in Smoldering Myeloma Is Independently Determined by the Chromosomal Abnormalities del(17p), t(4;14), Gain 1q, Hyperdiploidy, and Tumor Load
- (2013) Kai Neben et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma
- (2013) S V Rajkumar et al. LEUKEMIA
- Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study
- (2013) Benjamin M. Cherry et al. LEUKEMIA & LYMPHOMA
- Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging “early myeloma”
- (2013) Jens Hillengass et al. LEUKEMIA & LYMPHOMA
- Impact of global and gene-specific DNA methylation pattern in relapsed multiple myeloma patients treated with bortezomib
- (2013) Carlos Fernández de Larrea et al. LEUKEMIA RESEARCH
- Treatment for High-Risk Smoldering Myeloma
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
- (2013) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies
- (2013) O. Landgren Hematology-American Society of Hematology Education Program
- Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: A randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study
- (2012) Terry Golombick et al. AMERICAN JOURNAL OF HEMATOLOGY
- Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides
- (2012) J. B. Egan et al. BLOOD
- Myeloma as a model for the process of metastasis: implications for therapy
- (2012) I. M. Ghobrial BLOOD
- Clonal competition with alternating dominance in multiple myeloma
- (2012) J. J. Keats et al. BLOOD
- Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma: A Review of the Current Understanding of Epidemiology, Biology, Risk Stratification, and Management of Myeloma Precursor Disease
- (2012) A. Agarwal et al. CLINICAL CANCER RESEARCH
- Molecular pathogenesis of multiple myeloma and its premalignant precursor
- (2012) W. Michael Kuehl et al. JOURNAL OF CLINICAL INVESTIGATION
- SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status
- (2012) L López-Corral et al. LEUKEMIA
- A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma
- (2012) T E Witzig et al. LEUKEMIA
- Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma
- (2012) J T Larsen et al. LEUKEMIA
- Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
- (2011) M. Dimopoulos et al. BLOOD
- Tumor Metastasis: Molecular Insights and Evolving Paradigms
- (2011) Scott Valastyan et al. CELL
- Multiple Myeloma Mesenchymal Stem Cells: Characterization, Origin, and Tumor-Promoting Effects
- (2011) M. R. Reagan et al. CLINICAL CANCER RESEARCH
- Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma
- (2011) W-J Chng et al. LEUKEMIA
- Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study
- (2011) Giovanni D'arena et al. LEUKEMIA & LYMPHOMA
- Diagnosis of Smoldering Multiple Myeloma
- (2011) S. Vincent Rajkumar et al. NEW ENGLAND JOURNAL OF MEDICINE
- The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells
- (2010) E. Martinez-Garcia et al. BLOOD
- Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I - A randomized study
- (2010) Martin Hjorth et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients With Asymptomatic Multiple Myeloma
- (2010) Jens Hillengass et al. JOURNAL OF CLINICAL ONCOLOGY
- Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
- (2010) R A Kyle et al. LEUKEMIA
- Genetic variegation of clonal architecture and propagating cells in leukaemia
- (2010) Kristina Anderson et al. NATURE
- Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case
- (2009) L. Chiecchio et al. HAEMATOLOGICA
- Absence of methylation-dependent transcriptional silencing in TP73 irrespective of the methylation status of the CDKN2A CpG island in plasma cell neoplasia
- (2009) Eleftheria Hatzimichael et al. LEUKEMIA RESEARCH
- Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative Component
- (2009) John A. Lust et al. MAYO CLINIC PROCEEDINGS
- Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease
- (2008) B. Barlogie et al. BLOOD
- A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma
- (2008) Pellegrino Musto et al. CANCER
- MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis
- (2008) F. Pichiorri et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
- (2007) A. Dispenzieri et al. BLOOD
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started